Table 1

Study cohort of HLA-A*02-positive cHBV patients with low viral load 

Patient IDAge (years)SexVL (IU/mL)HBsAg (IU/mL)ALT (U/L)TherapyWT viral sequencesDetectable CD8+ T cell response
cHBV131M18635920.6636Naivecore18, env183core18
cHBV245F19653.9627Naivecore18, pol455core18, pol455
cHBV342F889925.2215Naivecore18core18
cHBV452F2425786.7736Naivecore18, env183core18
cHBV538M253014.0845Naivepol455
cHBV640F672888.6520Naiveenv183, pol455pol455
cHBV758F13610.8714Naiveenv183, pol455env183, pol455
cHBV855M5027751.1033Naiveenv183, pol455env183, pol455
cHBV953M4110.4521Naivecore18core18
cHBV1029F306652.6314Naivecore18, env183core18, env183
cHBV1177F367230.7920Naivecore18, pol455core18, pol455
cHBV1225F3467.4820Naivecore18, env183core18
cHBV1351M15790.8120Naivecore18core18
cHBV1455F87172.9822Naivecore18core18
cHBV1561M1335180.2856Naivecore18core18
cHBV1654M30128.8324Naivecore18core18
cHBV1728M270397.539Naivecore18core18
cHBV1863F92221.9628Naivecore18, env183, pol455core18
cHBV1934M345215.0783Naiveenv183, pol455pol455
cHBV2033F1085796.4921Naivecore18, env183, pol455core18, pol455
cHBV2142F2662233.6616Naiveenv183, pol455
cHBV2240M34724.3330Naiveenv183, pol455
cHBV2349Fnd605.378Naiveenv183, pol455
cHBV2446M137531 50156Naiveenv183, pol455
cHBV2536F445998.5138Naivecore18, env183env183
cHBV2640F1536667.2324Naivepol455
cHBV2758F184252.8019Naivepol455pol455
cHBV2847F657301.0611Naiveenv183env183
cHBV2940F189nd26Naiveenv183
cHBV3066M2932409.2219Adefovircore18, env183, pol455core18, pol455
cHBV3132M146315.7358Entecavirpol455pol455
cHBV3253Fnd963.4218Entecavircore18, env183, pol455pol455
cHBV3328F6658287.7944Entecavircore18, env183, pol455pol455
cHBV3447F502899.1722Entecavirpol455pol455
cHBV3553M<1015 623.5254Entecavircore18, env183, pol455core18, pol455
cHBV3653M<101394.331Entecavircore18core18
cHBV3746F122190.7633Entecavirenv183, pol455pol455
cHBV3837M<103444.0355Entecavirenv183, pol455
cHBV3927F<101432.9427Lamivudinepol455
cHBV4051M<10215.942Telbivudineenv183, pol455pol455
cHBV4131M602338.4431Telbivudineenv183, pol455pol455
cHBV4248M331123.6648Telbivudineenv183, pol455pol455
cHBV4342F<10163.4115Tenofovircore18, pol455core18, pol455
cHBV4430M<103049.4428Tenofovirenv183, pol455env183, pol455
cHBV4533F<103409.6156Tenofovircore18, env183, pol455core18, pol455
cHBV4641M<10927.0419Tenofovirenv183, pol455pol455
cHBV4761F<10483.2624Tenofovirenv183, pol455
cHBV4856F<10592.1230Tenofovirenv183, pol455env183
cHBV4943F<10138.7120Tenofovirenv183env183
  • ALT, alanine transaminase; cHBV, chronic HBV; F, female; HBsAg, HBV surface antigen; M, male; nd, not done; VL, viral load; WT, wild type.